CHINA PHARMA HOLDINGS INC

NYSE: CPHI (China Pharma Holdings, Inc.)

Kemas kini terakhir: 5 minit lalu

6.55

5.64 (619.78%)

Penutupan Terdahulu 0.910
Buka 0.860
Jumlah Dagangan 35,056,791
Purata Dagangan (3B) 2,428,793
Modal Pasaran 265,419,104
Harga / Jualan (P/S) 2.25
Harga / Buku (P/B) 1.00
Julat 52 Minggu
0.380 (-94%) — 6.55 (0%)
Margin Keuntungan -106.30%
Margin Operasi (TTM) -66.76%
EPS Cair (TTM) -2.22
Pertumbuhan Hasil Suku Tahunan (YOY) -17.10%
Jumlah Hutang/Ekuiti (D/E MRQ) 50.31%
Nisbah Semasa (MRQ) 0.560
Pulangan Atas Aset (ROA TTM) -18.22%
Pulangan Atas Ekuiti (ROE TTM) -59.83%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Bercampur Menaik
Drug Manufacturers - Specialty & Generic (Global) Bercampur Bercampur
Stok China Pharma Holdings, Inc. - -

AISkor Stockmoo

-0.1
Konsensus Penganalisis 0.0
Aktiviti Orang Dalam NA
Volatiliti Harga -5.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal 2.0
Purata -0.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
CPHI 265 M - - 1.00
YCBD 8 M - 0.320 0.640
TAK 53 B 4.61% - 1.14
HLN 44 B 0.68% 20.61 1.98
TEVA 37 B - 23.74 4.50
RDY 11 B 0.67% 23.93 2.63

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. The company also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. The company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
% Dimiliki oleh Orang Dalam 21.07%
% Dimiliki oleh Institusi 1.04%

Pemilikan

Nama Tarikh Syer Dipegang
Efg International Ag 31 Mar 2026 40
Danske Bank A/S 31 Mar 2026 1
Drw Securities, Llc 31 Mar 2026 0

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda